Dietary Intake in Older Patients with Dementia Prior to and After the Onset of Coronavirus Disease 2019

Miyagami, Taiju; Watari, Takashi; Yano, Shungo; Aoki, Nozomi; Sugano, Koji; Shibata, Nobuto; Kanai, Yoshikatsu; Yang, Kwang-Seok; Naito, Toshio

doi:10.1080/00185868.2023.2193352

Cited by 1 publication

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The food intake was quantified using a 10-point scale for the proportion of each main dish and side dish eaten, with a maximum score of 60 points per day. [ 13 ]…”

Section: Methodsmentioning

confidence: 99%

“…The food intake was quantified using a 10-point scale for the proportion of each main dish and side dish eaten, with a maximum score of 60 points per day. [13] In this descriptive study, continuous variables were reported as means and standard deviations; categorical variables were summarized as frequencies and percentages of the study population. All analysis were performed using R (Ver 4.1.3) and Microsoft Excel Office 365.…”

Section: Data Collectionmentioning

confidence: 99%

See 1 more Smart Citation

Treatment with ensitrelvir for COVID-19 in hospitalized patients of very advanced age: Case series

Tomita,

Miyazawa,

Sonoyama

2024

Medicine

View full text Add to dashboard Cite

Introduction: Ensitrelvir fumaric acid (ensitrelvir) is an orally active 3C-like protease inhibitor used to treat severe acute respiratory syndrome coronavirus 2 infection. Ensitrelvir was granted an emergency use authorization in Japan in 2022, but reports on the effectiveness and safety of ensitrelvir in actual clinical settings are limited. Methods: Here, we report a case series of 9 patients with laboratory-confirmed symptomatic coronavirus disease of 2019 (COVID-19) who completed a 5-day course of ensitrelvir at Tomita Hospital from November 2022 to April 2023. Data on clinical symptoms, oxygen saturation, and food intake were collected for 14 days, beginning on the first day of ensitrelvir administration. The outcome of COVID-19 in each patient was also evaluated during this period. Results: All patients were female, 80 years old or older, and the mean age was 90.2 ± 5.5 years. All patients received ensitrelvir within 2 days after the onset of COVID-19. At baseline, 7 among the 9 patients had their body temperature above 37.5 °C and all of them had oxygen saturation levels of 94% or higher. All patients recovered without worsening of COVID-19, and none received oxygen or additional antiviral drugs during the observation period; no deaths were reported within 14 days. After receiving ensitrelvir for 5 days, all patients had resolution of fever (<37 °C). There was no significant decrease in food intake of patients due to COVID-19. All patients maintained oxygen saturation above 93%. Conclusion: Our results provide information on the real-world usage of ensitrelvir in elderly, hospitalized patients with COVID-19, and suggests that ensitrelvir is an option for treatment of COVID-19 in these population.

show abstract

“…The food intake was quantified using a 10-point scale for the proportion of each main dish and side dish eaten, with a maximum score of 60 points per day. [ 13 ]…”

Section: Methodsmentioning

confidence: 99%

Section: Data Collectionmentioning

confidence: 99%